Akorn, Inc. a specialty pharmaceutical company and an undisclosed healthcare company have entered into a five-year contract manufacturing supply agreement. Under the terms of the five-year agreement, Akorn will be responsible for the manufacturing and supply of the ophthalmic drug product. Akorn is the ANDA holder and expects to begin supplying the product in the first half of 2009. Arthur S. Przybyl, Akorn’s President and Chief Executive Officer stated, “We are very pleased to have been selected as the contract manufacturer for this ophthalmic product. The completion of this agreement represents the fifth new ophthalmic partnership in 2008 for our contract manufacturing business. We continue to seek opportunities in ophthalmics, liquid and lyophilized injectable products in order to expand our contract pharmaceutical business segment revenues.”
